Tamar Bridge News is your trusted guide through the currents of UK news, committed to bridging the gap between information and insight with clarity, precision, and a human-centric approach.
Endo, Inc. has unveiled new clinical data on collagenase clostridium histolyticum (CCH) for treating plantar fibromatosis at the American Orthopaedic Foot & Ankle Society’s (AOFAS) annual scientific meeting, which is being held through September 14, 2024. The Phase 2 clinical trial, presented orally at the conference, examined the efficacy of CCH in patients with plantar fibromatosis, also known as Ledderhose disease. The study, a double-blind, randomised, placebo-controlled trial, aimed to evaluate CCH’s impact compared to a placebo in alleviating the condition’s symptoms. Dr. James P. Tursi, Executive Vice President of Global Research & Development at Endo, emphasised the significance of…